EPIZYME INC's ticker is EPZM and the CUSIP is 29428V104. A total of 105 filers reported holding EPIZYME INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $376,000 | -4.3% | 327,100 | +108.3% | 0.00% | – |
Q4 2021 | $393,000 | -51.1% | 157,000 | 0.0% | 0.00% | -100.0% |
Q3 2021 | $804,000 | -38.4% | 157,000 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $1,305,000 | -7.8% | 157,000 | -3.3% | 0.00% | 0.0% |
Q1 2021 | $1,415,000 | -18.7% | 162,400 | +1.3% | 0.00% | 0.0% |
Q4 2020 | $1,741,000 | -8.9% | 160,300 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $1,912,000 | -24.4% | 160,300 | +1.8% | 0.00% | -50.0% |
Q2 2020 | $2,528,000 | +15.3% | 157,400 | +11.4% | 0.00% | 0.0% |
Q1 2020 | $2,192,000 | -36.1% | 141,300 | +1.3% | 0.00% | -50.0% |
Q4 2019 | $3,432,000 | +143.9% | 139,500 | +2.3% | 0.00% | +300.0% |
Q3 2019 | $1,407,000 | -15.5% | 136,400 | +2.8% | 0.00% | -50.0% |
Q2 2019 | $1,665,000 | +3.2% | 132,700 | +1.8% | 0.00% | 0.0% |
Q1 2019 | $1,614,000 | +153.8% | 130,300 | +26.3% | 0.00% | +100.0% |
Q4 2018 | $636,000 | -33.6% | 103,200 | +14.2% | 0.00% | 0.0% |
Q3 2018 | $958,000 | -21.8% | 90,400 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $1,225,000 | -17.6% | 90,400 | +8.0% | 0.00% | -50.0% |
Q1 2018 | $1,486,000 | +41.5% | 83,700 | 0.0% | 0.00% | +100.0% |
Q4 2017 | $1,050,000 | -34.1% | 83,700 | 0.0% | 0.00% | -50.0% |
Q3 2017 | $1,594,000 | +58.3% | 83,700 | +25.5% | 0.00% | +100.0% |
Q2 2017 | $1,007,000 | -12.0% | 66,700 | 0.0% | 0.00% | 0.0% |
Q1 2017 | $1,144,000 | +41.8% | 66,700 | 0.0% | 0.00% | 0.0% |
Q4 2016 | $807,000 | +45.1% | 66,700 | +18.1% | 0.00% | 0.0% |
Q3 2016 | $556,000 | -4.0% | 56,500 | 0.0% | 0.00% | 0.0% |
Q2 2016 | $579,000 | -12.1% | 56,500 | 0.0% | 0.00% | 0.0% |
Q1 2016 | $659,000 | +45.8% | 56,500 | +100.4% | 0.00% | 0.0% |
Q4 2015 | $452,000 | +24.5% | 28,200 | 0.0% | 0.00% | 0.0% |
Q3 2015 | $363,000 | -35.9% | 28,200 | +19.5% | 0.00% | 0.0% |
Q2 2015 | $566,000 | +27.8% | 23,600 | 0.0% | 0.00% | 0.0% |
Q1 2015 | $443,000 | +86.1% | 23,600 | +87.3% | 0.00% | 0.0% |
Q4 2014 | $238,000 | -30.4% | 12,600 | 0.0% | 0.00% | 0.0% |
Q3 2014 | $342,000 | +44.3% | 12,600 | +65.8% | 0.00% | 0.0% |
Q2 2014 | $237,000 | +37.0% | 7,600 | 0.0% | 0.00% | 0.0% |
Q1 2014 | $173,000 | +143.7% | 7,600 | +123.5% | 0.00% | – |
Q4 2013 | $71,000 | – | 3,400 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 31,833,334 | $47,750,000 | 19.42% |
MPM BioImpact LLC | 3,425,202 | $3,939,000 | 1.06% |
Palo Alto Investors LP | 6,774,541 | $7,791,000 | 0.60% |
Foresite Capital Management I, LLC | 143,759 | $165,000 | 0.29% |
PLATINUM INVESTMENT MANAGEMENT LTD | 6,603,870 | $7,594,000 | 0.23% |
Rock Springs Capital Management LP | 7,267,696 | $8,358,000 | 0.21% |
BP PLC | 24,687 | $28,000 | 0.16% |
NewGen Asset Management Ltd | 250,000 | $288,000 | 0.13% |
GSA CAPITAL PARTNERS LLP | 467,836 | $538,000 | 0.07% |
Frazier Life Sciences Management, L.P. | 739,369 | $850,000 | 0.07% |